ArticleBMC infectious diseases2025
Clinical characteristics of patients with COVID-19-associated mucormycosis (CAM) hospitalized at Shafa Hospital, Kerman: 2022.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucormycosis, commonly known as 'black fungus,' has emerged as a significant health threat during the COVID-19 pandemic, with a marked increase in prevalence among infected individuals. This study focuses on identifying the characteristics of COVID-19-associated mucormycosis patients in Kerman.
methodsThis cross-sectional study was conducted at Shafa Hospital, Kerman, in 2022, following ethical approval from Kerman University of Medical Sciences. Patients with confirmed mucormycosis and positive COVID-19 PCR results were included using a census method. Diagnosis involved PCR testing, histopathological examination, and imaging studies. Data were collected from medical records by a trained student, ensuring anonymity. SPSS version 25 was used for analysis, with significance set at p < 0.05.
resultsAmong 37 patients with COVID-19-associated mucormycosis in 2022, 34 had complete medical records. The mean age was 58.8 ± 17.2 years, with a gender distribution of 58.8% female and 41.2% male. Mucormycosis was diagnosed 2-4 weeks after COVID-19 infection in 55.9% of cases. Pulmonary involvement was noted in 97.1% of patients, and corticosteroid use was prevalent in 85.3%. Diabetes and hypertension were present in 64.7% and 35.3% of patients, respectively. Opioid use was significantly higher in males (75.0%) compared to females (25.0%) (P = 0.042).
conclusionsThis study reveals a higher prevalence of mucormycosis among older adults and individuals with underlying health conditions, particularly those who are immunocompromised, following COVID-19. The timing of diagnosis suggests a link between COVID-19-related immune compromise and mucormycosis onset, highlighting the need for vigilant monitoring during recovery. The significant pulmonary involvement underscores the necessity for routine respiratory screenings in at-risk populations. Additionally, the higher opioid use among males indicates a need to reassess pain management protocols to consider their impact on immune function. Understanding these patterns can inform targeted interventions to improve patient outcomes in diverse healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.